Aethlon Medical, Inc. filed a Form S-8 registration statement on November 12, 2026, to register an additional 100,000 shares of common stock issuable under its 2020 Equity Incentive Plan, as amended.

Key Highlights

  • Additional shares registered: 100,000 shares of common stock, par value $0.001 per share, under the 2020 Equity Incentive Plan.
  • Stockholder approval: The amendment to the 2020 Plan authorizing the additional shares was approved by stockholders on October 1, 2026, at the company's 2026 Annual Meeting of Stockholders.
  • Three reverse stock splits: The company effected a one-for-eight reverse split effective June 6, 2025, a one-for-ten reverse split effective October 16, 2025, and a one-for-five reverse split effective July 31, 2026.
  • Prior S-8 filings: This registration supplements earlier S-8 filings dated September 15, 2020, September 19, 2022, November 15, 2024, and June 10, 2026.
  • Signing officer: James B. Frakes, Chief Executive Officer and Chief Financial Officer, signed the registration statement on behalf of the company.

Aethlon Medical Adds Shares to 2020 Equity Incentive Plan via New S-8

According to the filing, Aethlon Medical, Inc. (NASDAQ:AEMD) submitted this Form S-8 registration statement under General Instruction E, which permits the registration of additional shares on an existing plan by incorporating the contents of prior registration statements. The 100,000 newly registered shares of common stock, par value $0.001 per share, are issuable under the company's 2020 Equity Incentive Plan, as amended. The filing states that these shares are in addition to those previously registered under the four earlier S-8 filings referenced above.

The filing discloses that the stockholder approval of the plan amendment was described in a Current Report on Form 8-K filed with the Securities and Exchange Commission on October 1, 2026, as amended by a Form 8-K/A filed on October 5, 2026, both of which are incorporated by reference into this registration statement. The company also incorporated by reference its Annual Report on Form 10-K for the fiscal year ended March 31, 2026, its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, and several Current Reports on Form 8-K filed between June 10, 2026 and October 9, 2026.

The registration statement notes that the number of shares issuable under the 2020 Plan was adjusted to reflect three reverse stock splits completed by the company: a one-for-eight split with trading on a split-adjusted basis commencing June 9, 2025; a one-for-ten split with split-adjusted trading commencing October 20, 2025; and a one-for-five split with split-adjusted trading commencing August 4, 2026. The filing identifies James B. Frakes as the company's Chief Executive Officer, Chief Financial Officer, and a Director, and lists Edward G. Broenniman, Chetan Shah, Angela Rossetti, and Nicolas Gikakis as additional signatories in their respective director capacities.

What Was Disclosed

Aethlon Medical filed a Form S-8 on November 12, 2026, to register 100,000 additional shares of common stock under its stockholder-approved 2020 Equity Incentive Plan. The filing also disclosed three reverse stock splits completed between June 2025 and July 2026.